Status:
COMPLETED
Safety and Effectiveness Study of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes
Lead Sponsor:
AcuFocus, Inc.
Conditions:
Presbyopia
Eligibility:
All Genders
45-60 years
Phase:
NA
Brief Summary
The purpose of this study is to determine if the AcuFocus Corneal Inlay ACI 7000PDT will provide an effective method for the correction of presbyopia in patients who have normal distance vision but ne...
Detailed Description
The loss of near vision and the ability to perform tasks that require near vision is part of the normal aging process. This natural transformation in the eye occurs as a result of the loss of accommod...
Eligibility Criteria
Inclusion
- Subjects must be natural emmetropes needing a minimum magnitude of +1.00D to +2.50D of reading add.
- Subjects must have uncorrected near visual acuity worse than 20/40 and better than 20/100 in the eye to be implanted.
- Subject must have distance visual acuity correctable to at least 20/20 in both eyes.
- Subjects must have a preoperative spherical equivalent of plano defined as +0.50D to -0.75D with no more than 0.75D of refractive cylinder as determined by cycloplegic refraction in the eye to be implanted.
Exclusion
- Subjects with a difference of \> 1.00D between the spherical equivalent manifest refraction and the spherical equivalent cycloplegic refraction.
- Subjects with anterior segment pathology, including cataracts, in the eye to be implanted.
- Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease, or any corneal abnormalities (including endothelial dystrophy, guttata, recurrent corneal erosion, etc.) in the eye to be implanted.
- Subjects with ophthalmoscopic signs of keratoconus (or keratoconus suspect) in the eye to be implanted.
- Subjects with a history of chronic dry eye not responding to therapy.
- Subjects with distorted or unclear corneal mires on topography maps of the eye to be implanted.
- Subjects who require canthotomy to generate a corneal flap in the eye to be implanted.
- Subjects with macular degeneration, retinal detachment, or any other fundus pathology that would prevent an acceptable visual outcome in the eye to be implanted.
- Subjects who have undergone previous intraocular or corneal surgery including cataract and LASIK surgery.
- Subjects with a history of herpes zoster or herpes simplex keratitis.
- Subjects who have a history of steroid-responsive rise in intraocular pressure, preoperative IOP \> 21 mmHg, glaucoma, or is a glaucoma suspect.
- Subjects with a history of diagnosed diabetes, autoimmune disease, connective tissue disease, or clinically significant atopic syndrome.
- Subjects on chronic systemic corticosteroids or other immunosuppressive therapy that may affect wound healing, and any immunocompromised subjects.
- Subjects who are using ophthalmic medication(s) other than artificial tears for treatment of any ocular pathology including ocular allergy.
- Subjects using systemic medications with significant ocular side effects.
- Subjects who are pregnant, lactating, or of child-bearing potential and not practicing a medically approved method of birth control.
- Subjects with known sensitivity to planned study concomitant medications.
- Subjects who are participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT00850031
Start Date
January 1 2009
End Date
October 1 2013
Last Update
February 28 2018
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Vista Laser Eye Clinics
Melbourne, Victoria, Australia, 3185
2
The Eye Institute
Bondi Junction, Australia, 2022
3
Paracelsus Medizinische Privat-Universität, PMU, Universitätsklinikum
Salzburg, Austria, 5020
4
Universitats-Augenklinik, Department of Ophthalmology
Bochum, Germany, 44892